Rhinomed has a platform medical device technology that is protected globally by a family of over 60 patents and 57 design patents. Our nasal platform envisages multiple applications from simple stenting through to nasal drug delivery and sensor/diagnostics.
Our R&D programs seek to understand how the platform can be adapted to solve specific unmet clinical needs in the following markets:
Sleep & Sleep Architecture
The impact of sleep and respiratory
function on cognitive issues
Obstructive sleep apnea
Diagnostics and sensors
Rhinomed has leveraged its experience as a leading developer of nasal and respiratory technology to develop a range of solutions that specifically respond to the challenges faced in easily and effectively collecting samples and diagnosing Upper Respiratory Tract Disease.
The company is developing a novel high yield nasal swab. The new swab has several compelling benefits over products currently on market. It is:
– More comfortable, less invasive easier to use than nasal and nasopharyngeal swabs
– Unique in that it collects samples from both nostrils simultaneously
– Able to collect samples from a far greater surface area of the nose than normal swabs
– Able to be self administered easily, and in a standardised manner, thereby reducing the risk of infection of health workers
– Able to be used by a wide number of people everyday
The Rhinoswab can be deployed separately or as part of a kit with a vial and viral transport media. The Rhinoswab could play a critical role in an assurance strategy designed to contain and control a pandemic in which mass, high frequency testing is used to easily identify those who are positive and ensure that those who are negative can resume normal life as soon as possible.
Point of Care testing is a rapidly growing area of opportunity. However, the constraint with existing sample collection methodologies limit this potential. The Rhinomed platform can sit within the nose for significant periods of time and can radically open the window of opportunity for point of care diagnostics. The Rhinoswab technology provides a unique platform that can potentially house both existing and emerging diagnostic technologies.
The nose is a well recognised site for the delivery of medication and the Rhinomed proprietary drug delivery platform is capable of delivering medication into the nose in an inhaled form or via a trans-dermal or trans-mucosal method.
Many of the challenges related to exiting nasal drug delivery solutions such as loss at the back of the throat, complexity surrounding spray areas, and accuracy of dosing levels can be resolved by the Rhinomed platform.
Rhinomed’s in-situ delivery system ensures a specific level of API can be delivered in a controlled manner at a specific site.
Rhinomed has licensed its technology as a drug delivery platform in the US market for the delivery of cannabinoids to one of North America’s leading medical cannabis companies – Columbia Care (CCHW:NE). This agreement will enable Columbia Care to nasally deliver a range of cannabinoid formulations that target several significant markets.
We are always interested in working with innovative organisations and individuals who believe they can make a real difference.
Please CONTACT US to discuss how we might collaborate.